3D Medicines (HKSE:01244) Debt-to-Equity : 0.30 (As of Dec. 2023)

View and export this data going back to 2022. Start your Free Trial

What is 3D Medicines Debt-to-Equity?

3D Medicines's Short-Term Debt & Capital Lease Obligation for the quarter that ended in Dec. 2023 was HK$245.7 Mil. 3D Medicines's Long-Term Debt & Capital Lease Obligation for the quarter that ended in Dec. 2023 was HK$63.2 Mil. 3D Medicines's Total Stockholders Equity for the quarter that ended in Dec. 2023 was HK$1,024.6 Mil. 3D Medicines's debt to equity for the quarter that ended in Dec. 2023 was 0.30.

A high debt to equity ratio generally means that a company has been aggressive in financing its growth with debt. This can result in volatile earnings as a result of the additional interest expense.

The historical rank and industry rank for 3D Medicines's Debt-to-Equity or its related term are showing as below:

HKSE:01244' s Debt-to-Equity Range Over the Past 10 Years
Min: -0.03 Med: 0.09 Max: 0.3
Current: 0.3

During the past 4 years, the highest Debt-to-Equity Ratio of 3D Medicines was 0.30. The lowest was -0.03. And the median was 0.09.

HKSE:01244's Debt-to-Equity is ranked worse than
64.8% of 1074 companies
in the Biotechnology industry
Industry Median: 0.145 vs HKSE:01244: 0.30

3D Medicines Debt-to-Equity Historical Data

The historical data trend for 3D Medicines's Debt-to-Equity can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

3D Medicines Debt-to-Equity Chart

3D Medicines Annual Data

Trend

Dec20

Dec21

Dec22

Dec23

Debt-to-Equity

-0.02

-0.03

0.19

0.30

3D Medicines Semi-Annual Data
	Dec20	Dec21	Jun22	Dec22	Jun23	Dec23
Debt-to-Equity	Get a 7-Day Free Trial			-0.03	N/A	0.19	0.31	0.30

Competitive Comparison of 3D Medicines's Debt-to-Equity

For the Biotechnology subindustry, 3D Medicines's Debt-to-Equity, along with its competitors' market caps and Debt-to-Equity data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

3D Medicines's Debt-to-Equity Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, 3D Medicines's Debt-to-Equity distribution charts can be found below:

* The bar in red indicates where 3D Medicines's Debt-to-Equity falls into.

3D Medicines Debt-to-Equity Calculation

Debt to Equity measures the financial leverage a company has.

3D Medicines's Debt to Equity Ratio for the fiscal year that ended in Dec. 2023 is calculated as

Debt to Equity	=	Total Debt			/	Total Stockholders Equity
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	Total Stockholders Equity
	=	(245.662	+	63.249)	/	1024.585
	=	0.30

3D Medicines's Debt to Equity Ratio for the quarter that ended in Dec. 2023 is calculated as

Debt to Equity	=	Total Debt			/	Total Stockholders Equity
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	Total Stockholders Equity
	=	(245.662	+	63.249)	/	1024.585
	=	0.30

3D Medicines (HKSE:01244) Debt-to-Equity Explanation

In the calculation of Debt to Equity, we use the total of Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation divided by Total Stockholders Equity. In some calculations, Total Liabilities is used to for calculation.

Be Aware

Because a company can increase its ROE % by having more financial leverage, it is important to watch the leverage ratio when investing in high ROE % companies.

3D Medicines Debt-to-Equity Related Terms

Thank you for viewing the detailed overview of 3D Medicines's Debt-to-Equity provided by GuruFocus.com. Please click on the following links to see related term pages.

3D Medicines (HKSE:01244) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » 3D Medicines Inc (HKSE:01244) » Definitions » Debt-to-Equity

Comparable Companies

Traded in Other Exchanges

N/A

Address

No. 3 and No. 5, Laiyang Road, Shandong, Qingdao, CHN

Website

https://www.3d-medicines.com

3D Medicines Inc is a commercial-stage biopharmaceutical company that researches, develops, and commercialization of drugs in the field of managing cancer as a chronic disease. It develops differentiated immuno-oncology drugs, helping cancer patients live with prolonged survival time and quality of life.

3D Medicines (HKSE:01244) Headlines

No Headlines